Puffing on Juul pods is just as effective for reducing specific tobacco-related biomarkers as complete abstinence from smoking. That’s the conclusion from landmark study data released Saturday during the U.S. Society for Research on Nicotine & Tobacco 2019 Annual Meeting. Juul Pines for FDA Approval The small clinical study is the first to be undertaken by Juul Labs, maker of the popular nicotine vaporizer devices. The former Silicon Valley startup has three other studies currently ongoing and hopes to compile enough positive data to convince the FDA to approve Juul by a 2022 deadline. juul's revenues took a hit (heh)
The post What Juul’s Landmark Vaping Study Means for Tobacco Regulation appeared first on CCN
* First published on ccn.com
